OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 [Yahoo! Finance]
OS Therapies to spin off OS Animal Health into a standalone public company [Seeking Alpha]
OS Therapies to Spinoff OS Animal Health into Standalone Public Company [Yahoo! Finance]
OS Therapies GAAP EPS of -$0.21 misses by $0.08 [Seeking Alpha]